Navigation Links
Research in which the University of Navarra participated provides new clues to causes of leukemia
Date:6/1/2010

This release is available in Spanish.

The University of Navarra, together with the University of Oxford and three other European centres, are taking part in a project to discover the origin of myelodysplasia, an ailment with a predisposition to develop into leukaemia. In the work, patients from 19 hospitals in the north of Spain including the University Hospital of Navarra - were analysed, as well as from England, Italy, Sweden and Germany.

The aim of the research, published recently in the Leukemia journal, is to look for molecular-level alterations genetic mutations, etc. that enable the development of new therapeutic targets for the treatment of leukaemia, and provide, moreover, a tool for monitoring the progress of patients subjected to specific treatment.

There are currently very different treatments for the group of ailments that we know as leukaemia and that are caused by different alterations. The problem lies in that they cannot now be classified solely with systems based on clinical symptomatology, given that in some cases patients do not manifest any alteration that makes this classification useful from a therapeutic perspective. Consequently, it has to be observed in greater detail at a molecular level.

In this way, the research team at the University of Navarra confirmed that the presence of mutations in a determined gene is associated with more serious forms of leukaemia, giving rise to the possibility of a relation between these mutations and the advancing to the most serious stage of the ailment. Moreover, this gene is linked to the mechanisms that regulate the interaction between genes and the environment that surrounds us. In short, this is another finding that opens new doors to identifying the disease at its early stages.


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers find gene linked to birth defects
2. Yale researchers develop test to identify best sperm
3. First Arizona Strides for Life event nets $25,000 for TGen research
4. Canadian research examines effects of scientific claims on oil
5. Consent forms for research: Have they improved in 25 years?
6. DFG approves 12 new collaborative research centers
7. Medical researchers discovery may explain how certain cancers develop
8. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
9. UCI researchers create retina from human embryonic stem cells
10. Discovery may lead to safer drinking water, cheaper medicine: Queens University researchers
11. Researchers discover new mechanism for clearing blockages from smallest blood vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... Jan. 5, 2017  Delta ID Inc., a leader ... technology for automotive at CES® 2017. Delta ID has ... to demonstrate the use of iris scanning as a ... the driver in a car, and as a way ... experience. Delta ID and Gentex will demonstrate ...
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/16/2016)... Research and Markets has announced the addition ... to 2021" report to their offering. ... The biometric vehicle access system market, ... of 14.06% from 2016 to 2021. The market is estimated to ... 854.8 Million by 2021. The growth of the biometric vehicle access ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Ca (PRWEB) , ... January 18, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, was today ... News. The awards program is based entirely on merit and decided upon by ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/19/2017)... FRANKLIN LAKES, N.J. , Jan. 18, 2017 BD ... medical technology company, announced today that it will host a live ... 2017, at 1 p.m. (ET). The webcast can ... will be available for replay through Tuesday, January 31, 2017. ... About BD ...
Breaking Biology Technology: